Teva Appeals Singulair Patent Suit To Fed. Circ.

Law360, New York (September 21, 2009, 1:07 PM EDT) -- Teva Pharmaceutical Industries Ltd. has appealed an order barring it from making a generic version of Merck Sharpe & Dohme Pharmaceuticals SRL's allergy and asthma drug Singulair.

Teva filed a notice Friday in the U.S. District Court for the District of New Jersey, saying it would appeal the court's finding that Teva's proposed drug infringed a Merck patent to the U.S. Court of Appeals for the Federal Circuit.

An attorney for Merck could not immediately be reached for comment on Monday.

“The court appropriately ruled that...
To view the full article, register now.